Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Inamdar GS, Madhunapantula SV, Robertson GP.

Biochem Pharmacol. 2010 Sep 1;80(5):624-37. doi: 10.1016/j.bcp.2010.04.029. Epub 2010 May 9. Review.

2.

Current and future trials of targeted therapies in cutaneous melanoma.

Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ.

Adv Exp Med Biol. 2013;779:223-55. doi: 10.1007/978-1-4614-6176-0_10. Review.

3.

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.

Wang AX, Qi XY.

IUBMB Life. 2013 Sep;65(9):748-58. doi: 10.1002/iub.1193. Epub 2013 Jul 29. Review.

4.

Is B-Raf a good therapeutic target for melanoma and other malignancies?

Madhunapantula SV, Robertson GP.

Cancer Res. 2008 Jan 1;68(1):5-8. doi: 10.1158/0008-5472.CAN-07-2038. Review.

5.

Targeting MAPK pathway in melanoma therapy.

Cheng Y, Zhang G, Li G.

Cancer Metastasis Rev. 2013 Dec;32(3-4):567-84. doi: 10.1007/s10555-013-9433-9. Review.

PMID:
23584575
6.

Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.

Panka DJ, Atkins MB, Mier JW.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2371s-2375s. Review.

7.

Therapeutic targets in melanoma: map kinase pathway.

Haluska FG, Ibrahim N.

Curr Oncol Rep. 2006 Sep;8(5):400-5. Review.

PMID:
16901402
8.

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.

Jang S, Atkins MB.

Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30. Review.

PMID:
24080641
9.

Novel inhibitors in the treatment of metastatic melanoma.

Kalinsky K, Haluska FG.

Expert Rev Anticancer Ther. 2007 May;7(5):715-24. Review.

PMID:
17492934
10.

MEK and RAF inhibitors for BRAF-mutated cancers.

Belden S, Flaherty KT.

Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11. Review.

PMID:
23058743
11.

Targeting BRAF in melanoma: biological and clinical challenges.

MandalĂ  M, Voit C.

Crit Rev Oncol Hematol. 2013 Sep;87(3):239-55. doi: 10.1016/j.critrevonc.2013.01.003. Epub 2013 Feb 15. Review.

PMID:
23415641
12.

BRAF, a target in melanoma: implications for solid tumor drug development.

Flaherty KT, McArthur G.

Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261. Review.

13.

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.

Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA.

Discov Med. 2015 Jun;19(107):455-61. Review.

14.

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.

Pritchard AL, Hayward NK.

Clin Cancer Res. 2013 May 1;19(9):2301-9. doi: 10.1158/1078-0432.CCR-12-0383. Epub 2013 Feb 13. Review.

15.

The role of the PI3K-AKT pathway in melanoma.

Davies MA.

Cancer J. 2012 Mar-Apr;18(2):142-7. doi: 10.1097/PPO.0b013e31824d448c. Review.

PMID:
22453015
16.

Emerging Raf inhibitors.

McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.

Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Review.

PMID:
19715444
17.

Targeted therapies for cutaneous melanoma.

Kee D, McArthur G.

Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3. Review.

PMID:
24880943
18.

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.

Akabane H, Sullivan RJ.

Am J Clin Dermatol. 2016 Feb;17(1):1-10. doi: 10.1007/s40257-015-0159-z. Review.

PMID:
26518880
19.

Adaptive resistance to RAF inhibitors in melanoma.

Kugel CH 3rd, Aplin AE.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1032-8. doi: 10.1111/pcmr.12264. Epub 2014 Jun 6. Review.

20.

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Madhunapantula SV, Robertson GP.

Pigment Cell Melanoma Res. 2009 Aug;22(4):400-19. doi: 10.1111/j.1755-148X.2009.00585.x. Epub 2009 May 28. Review.

Supplemental Content

Support Center